• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by President Docherty John Martin

    5/16/25 5:19:02 PM ET
    $LEXX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $LEXX alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    DOCHERTY JOHN MARTIN

    (Last) (First) (Middle)
    23 MIKELEN DRIVE

    (Street)
    PORT PERRY A6 L9L 1V1

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Lexaria Bioscience Corp. [ LEXX ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    X Officer (give title below) Other (specify below)
    President
    3. Date of Earliest Transaction (Month/Day/Year)
    05/15/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    common shares 54,075 I Private Holding Company
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Options $3 04/26/2021 04/26/2026 Common Shares 18,000 18,000 D
    Stock Options $3 06/08/2021 06/08/2026 Common Shares 18,334 36,334 D
    Stock Options $3 09/01/2021 09/01/2026 Common Shares 15,000 51,334 D
    Stock Options $2.91 08/29/2022 08/29/2027 Common Shares 30,000 81,334 D
    Stock Options $1.15 10/26/2023 10/26/2028 Common Shares 30,000 111,334 D
    Stock Options $2.36 04/26/2024 04/26/2029 Common Shares 49,500 160,834 D
    Stock Options $1.04 05/15/2025 A 150,000 05/15/2025 05/15/2030 Common Shares 150,000 $0 310,834 D
    Explanation of Responses:
    /John Docherty/ 05/16/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $LEXX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $LEXX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $LEXX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Lexaria's Human GLP-1 Study #5 Receives Independent Review Board Approval

      Positive results in a recent animal study strongly supports first-ever human investigation for DehydraTECH-liraglutide in an oral capsule format KELOWNA, BC / ACCESSWIRE / January 15, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to announce that it has received the necessary independent ethics board approval required for its contract research organization ("CRO") to begin to implement and execute human pilot study GLP-1-H25-5 (the "Study"). The Study will compare an oral version of liraglutide, formulated from the DehydraTECH-processing of Saxenda® ("DehydraTECH-liraglutide") to the convent

      1/15/25 9:20:00 AM ET
      $LEXX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lexaria's Oral DehydraTECH-Tirzepatide Reduces Side Effects by Half with Comparable Efficacy Versus Eli Lilly's Injectable GLP-1/GIP Drug Zepbound(R)

      Oral DehydraTECH-tirzepatide evidenced reduced adverse events of 47% compared to injected Zepbound®Blood glucose reduction and insulin secretion levels from the oral DehydraTECH-tirzepatide were comparable to injected Zepbound® KELOWNA, BC / ACCESSWIRE / January 14, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces partial final results showcasing the tolerability and glycemic control efficacy findings from human study GLP-1-H24-3 (the "Study"), comparing an oral version of DehydraTECH-processed Zepbound® ("DehydraTECH-tirzepatide") to conventional injected Zepbound®.The injected Zepbound® produc

      1/14/25 9:10:00 AM ET
      $LEXX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lexaria's Registered GLP-1 Study #4 Begins Dosing

      Registered Phase-1b 12-week study will investigate safety, diabetes control, and weight loss KELOWNA, BC / ACCESSWIRE / December 19, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces it has begun dosing in the Company's Phase 1b, 12-week chronic study GLP-1-H24-4, (the "Study"). The Study is designed mainly to determine whether Lexaria's proprietary DehydraTECH technology improves the safety and effectiveness of existing GLP-1 drugs."Achieving the first patient, first dose Study milestone is a critical achievement," said John Docherty, President and Chief Scientific Officer of Lexaria Bioscience

      12/19/24 9:05:00 AM ET
      $LEXX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LEXX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Executive Officer Christopher Richard

      4 - Lexaria Bioscience Corp. (0001348362) (Issuer)

      5/16/25 5:47:41 PM ET
      $LEXX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Bunka Christopher

      4 - Lexaria Bioscience Corp. (0001348362) (Issuer)

      5/16/25 5:39:39 PM ET
      $LEXX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Secretary Carle Vanessa

      4 - Lexaria Bioscience Corp. (0001348362) (Issuer)

      5/16/25 5:27:43 PM ET
      $LEXX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LEXX
    SEC Filings

    See more
    • Lexaria Bioscience Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits

      8-K - Lexaria Bioscience Corp. (0001348362) (Filer)

      4/28/25 5:18:39 PM ET
      $LEXX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B5 filed by Lexaria Bioscience Corp.

      424B5 - Lexaria Bioscience Corp. (0001348362) (Filer)

      4/25/25 5:48:07 PM ET
      $LEXX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Lexaria Bioscience Corp.

      10-Q - Lexaria Bioscience Corp. (0001348362) (Filer)

      4/14/25 2:09:39 PM ET
      $LEXX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LEXX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Christopher Richard bought $118,392 worth of shares (50,000 units at $2.37) (SEC Form 4)

      4 - Lexaria Bioscience Corp. (0001348362) (Issuer)

      12/3/24 2:03:28 PM ET
      $LEXX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Turkel Catherine C. bought $5,008 worth of shares (1,600 units at $3.13), increasing direct ownership by 107% to 3,100 units (SEC Form 4)

      4 - Lexaria Bioscience Corp. (0001348362) (Issuer)

      8/13/24 10:55:35 AM ET
      $LEXX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LEXX
    Leadership Updates

    Live Leadership Updates

    See more
    • Esteemed Harvard Medical School Professor Dr. Michael Gibson Appointed Chief Medical Advisor at Lexaria Bioscience

      Dr. Gibson joining Lexaria's new scientific advisor board KELOWNA, BC / ACCESSWIRE / December 17, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces the appointment of Dr. Michael Gibson as its new Chief Medical Advisor. Dr. Gibson will collaborate directly with President John Docherty as Lexaria's patented DehydraTECH drug delivery platform continues to expand its applications in GLP-1 and hypertension.C. Michael Gibson M.S., M.D., is an interventional cardiologist, cardiovascular researcher & educator. He is the CEO of the combined non-profit Baim and PERFUSE research institutes at Harvard Medic

      12/17/24 9:10:00 AM ET
      $LEXX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lexaria Appoints Michael Shankman as Chief Financial Officer

      KELOWNA, BC / ACCESSWIRE / October 1, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX) & (NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces the appointment of Michael Shankman, CPA, as Chief Financial Officer (CFO) effective immediately. As a member of the executive leadership team, Mr. Shankman will lead the Company's financial operations."Mike is an accomplished individual who brings a wealth of financial and regulatory knowledge and experience to the table," said Richard Christopher, Chief Executive Officer of Lexaria. "On behalf of the entire Lexaria team, I'm thrilled to welcome Mike as our CFO as we continue to strengthen our executive tea

      10/1/24 9:25:00 AM ET
      $LEXX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lexaria Appoints Nelson Cabatuan as Chief Financial Officer

      KELOWNA, BC / ACCESSWIRE / March 14, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces the appointment of Nelson Cabatuan, CPA, as Chief Financial Officer (CFO) effective immediately. As a member of the executive leadership team, Mr. Cabatuan will lead the Company's financial operations."Nelson's deep financial leadership experience will be instrumental to the execution of Lexaria's long-term growth strategy as we continue to maximize the potential use of our DehydraTECH platform for GLP-1 and other therapeutic applications with high unmet medical needs," said Chris Bunka, Chief Executive Officer

      3/14/24 9:20:00 AM ET
      $LEXX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LEXX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Lexaria Bioscience Corp.

      SC 13G/A - Lexaria Bioscience Corp. (0001348362) (Subject)

      11/14/24 4:11:11 PM ET
      $LEXX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Lexaria Bioscience Corp.

      SC 13D/A - Lexaria Bioscience Corp. (0001348362) (Subject)

      9/23/24 1:28:02 PM ET
      $LEXX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Lexaria Bioscience Corp.

      SC 13D/A - Lexaria Bioscience Corp. (0001348362) (Subject)

      8/6/24 4:11:10 PM ET
      $LEXX
      Biotechnology: Pharmaceutical Preparations
      Health Care